Lesson
Recognize Inflammatory Arthritis Early
Rheumatoid arthritis is a systemic autoimmune disease whose joint pattern, duration, and objective inflammation distinguish it from many common pain conditions. Early recognition protects function and structure.
- Synovitis
- Morning stiffness
- Symmetry
- Serology
- Extra-articular disease
Map swelling, warmth, stiffness, symmetry, and duration.
Use serology, markers, imaging, and examination together.
A hot swollen joint with infection risk changes the immediate plan.
Read the joint pattern
Persistent warmth, tenderness, swelling, and prolonged morning stiffness often involve the MCP, PIP, wrist, ankle, and forefoot joints. Symmetry is common, but an incomplete early pattern does not exclude disease.
Separate classification from diagnosis
Rheumatoid factor and anti-citrullinated protein antibodies support classification and prognosis. Neither is perfectly specific or sensitive. Negative antibodies or normal inflammatory markers do not exclude RA and should not delay referral for persistent clinical synovitis. Use laboratory results with examination, imaging, symptom duration, and alternative diagnoses.
Find dangerous mimics
Acutely hot monoarthritis, fever, bacteremia risk, possible crystal arthritis, trauma, or severe immunosuppression changes the immediate question. Septic arthritis must be excluded urgently when clinically plausible.
Look beyond joints
Rheumatoid nodules, lung disease, ocular inflammation, neuropathy, vasculitis, anemia, and accelerated cardiovascular risk can alter both prognosis and treatment selection.
Quick check
Checking for saved practice…
Lesson
Treat to a Measured Target
Disease modification succeeds when the team defines remission or low disease activity, measures progress consistently, and changes therapy when the target remains out of reach.
- Remission
- Low disease activity
- Three months
- Six months
- Shared decisions
Record joints, function, symptoms, and relevant markers.
Audit diagnosis, exposure, response, and tolerability.
Adjust disease-modifying therapy when remission or low activity remains out of reach.
Define the target
Use a validated disease-activity measure with joint counts, function, symptoms, and relevant laboratory data. The target is usually remission or low disease activity, adjusted to the patient's context.
Use the response timeline
Active disease is monitored frequently, often every one to three months. Lack of meaningful improvement by about three months or failure to reach target by six months should prompt reassessment and treatment adjustment.
Start promptly and define escalation
Begin DMARD treatment promptly once RA is diagnosed. EULAR 2025 recommends adding a biologic when the conventional strategy misses target, without the older prognostic-factor gate. U.S. JAK labeling remains more restrictive. Reassess response and safety rather than repeating an ineffective class indefinitely.
Choose a meaningful activity measure
Use ACR/EULAR remission definitions, such as Boolean or CDAI/SDAI criteria. A normal CRP or DAS28-based remission alone can be misleading during IL-6 or JAK inhibition. Imaging can answer selected questions, but routinely escalating treatment to eliminate all ultrasound or MRI abnormalities is not the target.
Confirm real exposure
Before declaring failure, verify diagnosis, adherence, dose, route, duration, access, adverse effects, and whether inflammation rather than structural or centralized pain explains persistent symptoms.
Integrate function
Regular exercise, physical therapy, occupational therapy, joint protection, and assistive strategies complement pharmacologic control. They do not substitute for effective DMARD therapy.
Quick check
Checking for saved practice…
Lesson
Use Methotrexate as a Weekly System
Methotrexate remains the anchor for many patients with moderate to high disease activity. Its effectiveness depends on correct weekly use, folate support, route optimization, and disciplined safety monitoring.
- Once weekly
- Folic acid
- Oral and subcutaneous
- Renal elimination
- Monitoring
Name the day, route, folate plan, and administration method.
Verify exposure, split over one day, or use subcutaneous delivery when appropriate.
Track blood counts, liver, kidney, infection, pregnancy, lungs, and interactions.
Protect the weekly schedule
For rheumatoid arthritis, methotrexate is taken once weekly. Choose and document a specific day, verify every medication list, and treat any daily instruction as an urgent clarification because daily errors have caused fatal toxicity.
Optimize the weekly dose
For appropriate adults, the 2021 ACR guideline conditionally favors reaching at least 15 mg weekly within four to six weeks over remaining below that dose. This is a treatment strategy, not permission to ignore renal function, cytopenias, liver disease, tolerability, or the selected product label. Document the exact weekly dose and route.
Build a tolerable regimen
Folic acid reduces selected mucosal, gastrointestinal, and hepatic effects. When oral exposure or tolerance is limiting, a divided oral dose over one day or subcutaneous delivery may improve the regimen.
Specify folate and the monitoring protocol
Write a separate folic acid prescription and calendar. The 2025 BSR guideline recommends at least 5 mg once weekly on a different day from methotrexate; local regimens may differ. Its low-risk monitoring framework checks blood count, electrolytes, renal function, transaminases and albumin at week two, then monthly for three to six months, with an extra check two weeks after dose increases. Higher-risk patients need more frequent testing. Apply the selected product label and treating service protocol rather than substituting a generic schedule.
Monitor the organs that clear and tolerate it
Review blood counts, liver tests, renal function, alcohol, infection, pregnancy, pulmonary symptoms, and interacting medicines at baseline and more often after initiation or dose change.
Review interacting medicines
Methotrexate toxicity can increase with penicillin or sulfonamide antibiotics, other antifolates, probenecid, NSAIDs, proton-pump inhibitors, and nephrotoxic or hepatotoxic products. Review each new prescription and nonprescription medicine in the context of dose and kidney function. Avoid nitrous oxide anesthesia during methotrexate treatment because it can amplify antifolate toxicity. Notify procedural teams of the exposure.
Distinguish interaction risk from an absolute ban
Cyclosporine can increase methotrexate exposure and adds renal and other toxicity concerns, but the reviewed modified-cyclosporine label permits selected RA combination treatment after inadequate methotrexate response. This requires specialist dosing and monitoring; it is not a routine preferred escalation. Furosemide labeling describes competition involving renal tubular secretion, potentially reducing diuretic effect and increasing toxicity risk. Review kidney function, volume status, response and the full regimen rather than assuming every interaction has the same severity.
Do not equate topical and systemic exposure
Topical tacrolimus has low systemic absorption and lacks formal topical interaction studies; systemic interactions are unlikely but cannot be excluded. Its label nevertheless says not to use it in immunocompromised patients. Concurrent methotrexate therefore needs dermatology and rheumatology review, not an assumption that topical treatment is harmless or that a measured pharmacokinetic interaction has been established.
Teach the exact injection device
Rasuvo and Otrexup are once-weekly subcutaneous methotrexate devices for the abdomen or thigh, not the arm. Demonstrate the specific device and have the learner teach back the steps. Rasuvo may take up to five seconds; watch its transparent control zone until movement stops, and contact the treating team rather than use another device if liquid remains. Otrexup requires holding for three seconds after activation and checking its delivery indicator; do not repeat a suspected incomplete dose without contacting the treating team. Do not transfer timing or indicator rules between devices.
Recognize toxicity early
Mouth ulcers, severe nausea, bruising, infection, cytopenias, liver injury, new pulmonary symptoms, or acute kidney injury require prompt reassessment. Reduced renal clearance can magnify toxicity.
Quick check
Checking for saved practice…
Lesson
Match the Conventional DMARD to the Patient
Hydroxychloroquine, sulfasalazine, and leflunomide expand the conventional DMARD strategy, but each carries a distinct relationship among disease activity, organ safety, monitoring, and reproductive planning.
- Hydroxychloroquine
- Sulfasalazine
- Leflunomide
- Combination therapy
- Reproductive safety
Match dose and eye surveillance to weight, duration, kidney function, and risk.
Separate expected discoloration from systemic or mucosal toxicity.
Inhibit pyrimidine synthesis, then plan for a metabolite that can persist.
Use hydroxychloroquine deliberately
Hydroxychloroquine can fit lower disease activity or combination therapy. The AAO 2025 revision recommends no more than 5 mg/kg/day using actual weight, with a dose below 400 mg/day in severe obesity. Recalculate after major weight changes; this retinal-risk limit does not replace assessment of disease control and the product label.
Reconcile hydroxychloroquine dose and formulation
The reviewed RA label lists 400-600 mg/day initially and 200-400 mg/day chronically, but also warns that doses above 5 mg/kg actual weight increase retinal risk. Do not let a fixed tablet regimen override individualized weight and safety review. Take with food or milk. Check the selected tablet instructions before splitting; the reviewed product must not be divided or crushed.
Look beyond the retina
Hydroxychloroquine can cause cardiomyopathy, QT-related arrhythmias, severe skin reactions, myopathy, psychiatric reactions, and hypoglycemia even without diabetes medicines. Review other QT-prolonging drugs and assess new palpitations, fainting, weakness, severe rash, mood changes, or low-glucose symptoms promptly.
Arrange retinal surveillance
Obtain a baseline ophthalmic assessment soon after starting hydroxychloroquine, including optical coherence tomography (OCT) and fundus autofluorescence (FAF). Annual OCT and wide-pattern FAF are recommended during use; annual testing may be deferred in the first five years only when significant risk factors are absent. Kidney disease, tamoxifen, older age at initiation, dose, and duration increase concern. Visual fields or multifocal electroretinography can confirm suspicious findings. Coordinate decisions about suspected toxicity with ophthalmology and rheumatology.
Titrate sulfasalazine
For adult RA, the delayed-release Azulfidine EN-tabs label uses a low initial total dose of 500-1000 mg/day to improve tolerance, then 1 g twice daily. If response remains inadequate after 12 weeks, up to 3 g/day can be considered with closer toxicity monitoring. Swallow delayed-release tablets whole; preserve hydration and review contraindications.
Schedule sulfasalazine tests
The reviewed label calls for CBC with differential and liver tests before treatment, every two weeks for the first three months, monthly for the next three months, and every three months thereafter or more often when clinically indicated. Periodically assess urine and kidney function. Fever, sore throat, pallor, purpura, jaundice, or severe rash requires prompt assessment rather than waiting for the next routine test.
Check sulfasalazine contraindications
Do not use sulfasalazine with hypersensitivity to the drug, its metabolites, sulfonamides or salicylates, intestinal or urinary obstruction, or porphyria. Clarify the actual allergy history. Hepatic or renal damage and blood dyscrasias require careful risk assessment; worsening kidney function, serious infection, or suspected severe toxicity warrants interruption and prompt review.
Monitor sulfasalazine
Sulfasalazine requires blood-count and liver monitoring, allergy review, and counseling about gastrointestinal effects, rash, folate issues, reversible oligospermia, and expected discoloration. Systemic illness or mucosal rash is not benign discoloration.
Connect leflunomide structure to function
Leflunomide is an isoxazole prodrug converted to teriflunomide. Its active metabolite inhibits mitochondrial dihydroorotate dehydrogenase, limiting de novo pyrimidine synthesis needed by proliferating lymphocytes. This bioactivation and long persistence explain both its disease-modifying effect and its elimination challenge.
Dose and monitor leflunomide
Maintenance is 20 mg daily, reduced to 10 mg if intolerable. A 100-mg daily loading course for three days is reserved for low-risk patients; omit loading with increased hepatic or marrow risk. Check ALT and blood counts at baseline, monthly for six months, then every 6 to 8 weeks; concomitant immunosuppressants require continued monthly blood counts. Avoid initiation with pre-existing liver disease or ALT above twice normal. ALT above three times normal requires interruption and investigation; suspected drug injury requires accelerated elimination and weekly liver testing until recovery. With leflunomide, rosuvastatin must not exceed 10 mg daily.
Respect leflunomide persistence
Screen pregnancy, liver function, blood counts, blood pressure, and infection risk before and during therapy. Teriflunomide undergoes extensive recycling and can remain for a prolonged period. Severe toxicity or pregnancy can require cholestyramine or activated charcoal accelerated elimination followed by verification of low plasma concentrations.
Execute accelerated elimination
When indicated, the reviewed leflunomide label specifies cholestyramine 8 g orally three times daily for 11 days, or activated charcoal suspension 50 g orally every 12 hours for 11 days. Verify teriflunomide below 0.02 mg/L on two measurements at least 14 days apart; repeat elimination if concentrations remain above the threshold. Clinical status and tolerance can require adjustment. Simply counting elapsed time after the last tablet does not establish clearance.
Distinguish conventional combinations from dual biologics
An advanced DMARD is generally combined with a conventional DMARD when feasible. If conventional co-therapy cannot be used, IL-6 inhibitors or JAK inhibitors may offer monotherapy advantages, subject to individual risks and U.S. labeling. This does not authorize combining two biologics or a biologic with a JAK inhibitor.
Build combinations with purpose
Conventional combinations can improve control when one agent is insufficient. Every added drug must have a defined goal, monitoring plan, interaction review, and stop criterion.
Quick check
Checking for saved practice…
Lesson
Choose One Biologic Mechanism at a Time
Biologic DMARDs suppress distinct extracellular or cellular immune pathways. Mechanism helps explain efficacy, screening, adverse effects, vaccine response, and rational sequencing.
- TNF inhibitors
- Abatacept
- IL-6 inhibitors
- Rituximab
- Biosimilars
Bind TNF, IL-6 receptor, or CD20 with target-specific consequences.
Etanercept traps TNF while abatacept engages CD80 and CD86.
JAK inhibitors cross the membrane to alter kinase signaling.
Block TNF with context
Adalimumab, etanercept, infliximab, certolizumab, and golimumab differ in molecular structure, route, schedule, immunogenicity, and labeled uses. Screen tuberculosis and relevant hepatitis risk, and consider heart failure and demyelinating disease.
Read the molecular format
Monoclonal antibodies can bind a cytokine, receptor, or cell-surface target. Etanercept and abatacept are fusion proteins that pair an extracellular receptor-domain function with an immunoglobulin Fc region. Molecular format influences target engagement, route, dosing, immunogenicity, and handling, but it does not determine clinical value by itself.
Interrupt T-cell costimulation
Antigen recognition is not enough for full naive T-cell activation. CD80 and CD86 on an antigen-presenting cell provide a costimulatory signal through CD28. Abatacept is a CTLA-4 immunoglobulin fusion protein that binds CD80 and CD86, reducing this second signal before downstream cytokine amplification.
Block IL-6 receptor signaling
Tocilizumab and sarilumab can change neutrophils, platelets, liver tests, lipids, and inflammatory markers. New severe abdominal pain requires urgent assessment because gastrointestinal perforation can occur.
Deplete B cells
Rituximab targets CD20-positive B cells. U.S. labeling uses it with methotrexate after inadequate TNF-antagonist response. Infusion reactions, hepatitis B reactivation, severe skin reactions, PML, and vaccine timing require planning.
Know the IL-1 option
Anakinra blocks the IL-1 receptor and is labeled for adult RA after failure of at least one DMARD. The usual dose is 100 mg subcutaneously daily; consider every-other-day administration when creatinine clearance is below 30 mL/min. Avoid combination with TNF inhibitors and do not initiate during active infection. Check neutrophils before treatment, monthly for three months, then quarterly through the first year. Serious infection requires treatment interruption.
Distinguish etanercept schedules
Adult RA dosing for Enbrel is 50 mg subcutaneously once weekly. The twice-weekly initial plaque-psoriasis schedule must not be transferred to RA.
Read the exact storage presentation
The reviewed Enbrel label permits specified single-dose syringes, autoinjectors, vials, and Mini cartridges one room-temperature period of up to 30 days at 20-25 C. Its unreconstituted multiple-dose vial tray has a 14-day limit at that temperature. Do not return these room-temperature products to refrigeration. Mixed multiple-dose vials have separate refrigerated instructions. Record removal dates, protect from light and heat, and never extrapolate these limits to every biologic or biosimilar.
Use biosimilars accurately
An approved biosimilar has no clinically meaningful difference from its reference product in safety, purity, and potency. Interchangeability is a separate regulatory designation, and devices may still differ.
Quick check
Checking for saved practice…
Lesson
Build the Exact TNF-Inhibitor Regimen
TNF inhibitors share a target but not a prescription. Identify adult RA, the exact product, route, loading phase, maintenance interval, and accompanying methotrexate before calculating a dose.
- Indication
- Route
- Loading
- Maintenance
- Product identity
Simponi and Simponi Aria use different regimens.
Check kilograms, dose units, and any labeled limit.
Record actual dates and the last administered dose.
Adalimumab
Humira adult RA dosing is 40 mg subcutaneously every other week. Some patients not receiving methotrexate may benefit from 40 mg weekly or 80 mg every other week. Its refrigerated product may be kept up to 14 days at no more than 25 C, protected from light; record the removal date. Biosimilar storage and devices require their own labels.
Infliximab
Remicade adult RA dosing with methotrexate starts at 3 mg/kg IV at weeks 0, 2, and 6, then every eight weeks. Incomplete response may justify up to 10 mg/kg every eight weeks or intervals as short as four weeks, with greater serious-infection risk. Doses above 5 mg/kg are contraindicated in moderate or severe heart failure.
Prepare an infusion safely
For Remicade, reconstitute with sterile water and dilute in 0.9% sodium chloride using the label procedure. Administer over at least two hours through the specified low-protein-binding filter of 1.2 micrometers or less. Have a reaction-management plan. Do not transfer preparation instructions to a different product without checking its label.
Certolizumab
Cimzia adult RA loading is 400 mg subcutaneously at weeks 0, 2, and 4, each as two 200-mg injections. Maintenance is 200 mg every other week; 400 mg every four weeks is an alternative. A loading schedule is not a permanent maintenance frequency.
Golimumab
For adult RA, Simponi is 50 mg subcutaneously monthly with methotrexate. Simponi Aria is a separate IV product: 2 mg/kg over 30 minutes at weeks 0 and 4, then every eight weeks, also with methotrexate. Do not exchange the products milligram for milligram. Simponi Aria uses a sterile low-protein-binding in-line filter of 0.22 micrometer or less; its label allows dilution in 0.9% or 0.45% sodium chloride to 100 mL. Do not share its infusion line with other agents.
Teach the product-specific injection site
Humira is injected into the thigh or abdomen, rotating sites and avoiding tender, bruised, red or hard skin. Reviewed Enbrel devices use the thigh or abdomen for self-injection; the upper-arm site requires another person to administer it. Follow the exact device instructions for cap removal, warming time, injection angle, completion indicator and sharps disposal. Never extrapolate one device demonstration to every brand or presentation.
Separate Simponi devices
Current Simponi SmartJect instructions use the thigh or lower abdomen, not the arm, and specifically prohibit pinching the skin during injection because of device-failure and injury risk. Prefilled-syringe instructions differ and permit the back of the upper arm when someone else administers it. Use the current instructions supplied with the exact device; an older training leaflet or another device demonstration can give the wrong technique.
Reconcile the calendar
Etanercept weekly, adalimumab every other week, and golimumab monthly schedules are not interchangeable. Record exact dates and the last actual dose. An overdue injection, infection-related hold, and planned switch require different instructions; resolve these before giving a catch-up dose.
Quick check
Checking for saved practice…
Lesson
Check Non-TNF Biologic Doses and Thresholds
Drug-specific thresholds determine whether a planned biologic dose can proceed. The same target or route does not establish identical dosing, monitoring, or initiation criteria.
- Abatacept
- Rituximab
- IL-6 blockade
- Laboratory thresholds
Sarilumab and tocilizumab have different platelet cutoffs.
Assess trends, symptoms, and the specific abnormality.
A restart threshold is not an initiation threshold.
Abatacept routes
Adult RA IV abatacept is 500 mg below 60 kg, 750 mg at 60-100 kg, or 1,000 mg above 100 kg, infused over 30 minutes at weeks 0, 2, and 4 and every four weeks thereafter. Subcutaneous dosing is 125 mg weekly. IV loading before subcutaneous treatment is optional; if used, the first injection follows within one day.
Prepare IV abatacept with its own equipment
Reconstitute Orencia using the supplied silicone-free syringe, then dilute in 0.9% sodium chloride according to its label. Gently mix without shaking. For RA, infuse over 30 minutes through a sterile low-protein-binding filter with a pore size of 0.2 to 1.2 micrometers. Complete the infusion within 24 hours of reconstitution and do not co-infuse other agents in the same line.
Rituximab courses
For labeled adult RA use with methotrexate after TNF-antagonist failure, a course comprises two 1,000-mg IV infusions two weeks apart. Repeat at 24 weeks or according to response, never sooner than 16 weeks. Premedication includes acetaminophen and an antihistamine; IV methylprednisolone 100 mg or equivalent 30 minutes before each infusion is recommended. Screen all patients for hepatitis B before treatment.
Control the rituximab infusion rate
The standard first Rituxan infusion starts at 50 mg/hour, increasing by 50 mg/hour every 30 minutes if tolerated, to 400 mg/hour maximum. Standard subsequent infusions start at 100 mg/hour and increase by 100 mg/hour every 30 minutes to that maximum. Infusion reactions require interruption or slowing and severity-based treatment; restarting after improvement requires the supervised protocol, not automatic continuation. In RA, check CBC with differential and platelets every two to four months and continue surveillance until cytopenias resolve.
Tocilizumab routes
Adult RA IV tocilizumab begins at 4 mg/kg every four weeks over 60 minutes and may increase to 8 mg/kg; do not exceed 800 mg per infusion. Subcutaneous dosing is 162 mg every other week below 100 kg, with escalation to weekly by response; at 100 kg or above it is weekly. Never use the subcutaneous presentation for IV infusion.
Sarilumab and initiation tests
Adult RA sarilumab is 200 mg subcutaneously every two weeks. Initiation is not recommended with platelets below 150,000/mm3, ANC below 2,000/mm3, or ALT/AST above 1.5 times ULN. The tocilizumab RA platelet initiation boundary is 100,000/mm3; its ANC and transaminase boundaries match these sarilumab values. Do not use a class-wide platelet cutoff.
Interruption is a different decision
Initiation and on-treatment thresholds are different. For example, sarilumab ANC 500-1,000/mm3 requires holding treatment; after recovery above 1,000, the label permits restarting at 150 mg every two weeks, with later adjustment. ANC below 500 requires discontinuation. Apply the complete drug-specific table to the actual abnormality.
Schedule IL-6 safety testing
For adult RA tocilizumab, check neutrophils and platelets at baseline, after four to eight weeks, then every three months. Liver panels are checked before treatment, every four to eight weeks for the first six months, then every three months. Check lipids after four to eight weeks and manage subsequent testing and treatment under lipid guidance. Symptoms or abnormal trends can require earlier review; a routine due date does not override a new safety concern.
Distinguish sarilumab surveillance
For sarilumab, obtain baseline neutrophils, platelets, ALT/AST and lipids. Recheck counts and transaminases at four to eight weeks, then every three months; lipids at four to eight weeks, then approximately every six months. When considering a neutrophil-based dose change, use a result from the end of the dosing interval. Tocilizumab liver surveillance during its first six months is more frequent than this sarilumab schedule.
Keep the monitoring loop closed
Check the result, its trend, symptoms, timing, and the drug-specific action before releasing the next dose. New infection or severe abdominal pain can require urgent assessment despite reassuring inflammatory markers. Document who will review follow-up tests and authorize restart.
Quick check
Checking for saved practice…
Lesson
Treat Oral Targeted Therapy as Advanced Immunosuppression
JAK inhibitors act inside the cell to alter cytokine signaling. Oral administration does not make them simple or low risk, and current U.S. labeling places important boundaries around RA use.
- JAK signaling
- Serious infection
- MACE
- Malignancy
- Thrombosis
Reach intracellular kinase targets that large biologic proteins do not.
Reduce cytokine messages before transcription changes.
Track major risks, laboratory changes, metabolism, interactions, and symptoms.
Map the signal
Cytokine receptors recruit Janus kinases and STAT proteins to transmit extracellular immune signals into transcriptional change. Different inhibitors have product-specific selectivity and interaction profiles.
Contrast large and small molecules
Biologic proteins generally engage extracellular cytokines, receptors, or cell-surface targets and require parenteral delivery. Orally available JAK inhibitors are small molecules that enter cells and inhibit intracellular kinase signaling. This reach also creates product-specific metabolism, transporter, and drug-interaction considerations.
Apply the boxed warning
FDA warnings for JAK inhibitors used in chronic inflammatory conditions include serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Age, smoking, cardiovascular disease, malignancy, and clot history matter.
Follow current U.S. sequencing
For rheumatoid arthritis, current U.S. labels for agents such as upadacitinib use them after inadequate response or intolerance to one or more TNF blockers. EULAR also requires careful major-risk consideration.
Dose tofacitinib by formulation and clearance
For adult RA with usual organ function, tofacitinib is 5 mg twice daily or XR 11 mg once daily. Moderate or severe renal impairment requires the immediate-release 5 mg once-daily regimen; the label defines moderate impairment as creatinine clearance 30-50 mL/min. Selected CYP inhibitors also require reduction. Strong CYP3A4 inducers such as rifampin are not recommended, rather than managed by an improvised higher dose. Product switching requires the prescriber; do not apply ulcerative-colitis induction doses to RA.
Dose baricitinib for RA
The usual adult RA dose is 2 mg daily. Reduce to 1 mg daily at eGFR 30 to below 60 mL/min/1.73 m2; RA use is not recommended below 30. Strong OAT3 inhibitors such as probenecid also change dosing. Baricitinib schedules for COVID-19 and alopecia areata differ and must not be transferred to RA.
Dose upadacitinib for RA
Adult RA dosing is 15 mg once daily as an extended-release tablet. No adjustment is required for eGFR 15 to below 90 mL/min/1.73 m2; end-stage renal disease was not studied. Severe hepatic impairment is not recommended. Strong CYP3A4 inducers are not recommended; strong inhibitors require close adverse-effect monitoring for RA. Swallow tablets whole and do not substitute the oral solution or borrow inflammatory bowel disease induction doses.
Review new glucose risk
June 2026 tofacitinib and upadacitinib labeling updates warn about hypoglycemia, including severe episodes, after initiation in patients with diabetes. Consider additional glucose monitoring and review symptoms and diabetes therapy with the treating team.
Check JAK blood-count boundaries
Before RA treatment, all three reviewed JAK labels advise against initiation with ALC below 500 cells/mm3 or ANC below 1,000 cells/mm3. Tofacitinib also uses a hemoglobin initiation boundary of 9 g/dL; baricitinib and upadacitinib use 8 g/dL. Tofacitinib interruption rules differ from initiation: hemoglobin below 8 g/dL or a fall exceeding 2 g/dL requires a hold until normalized. Do not transfer a COVID-19 baricitinib threshold to RA or assume that initiation and restart rules are identical.
Use the correct JAK laboratory calendar
Tofacitinib requires lymphocyte assessment at baseline and every three months; neutrophils and hemoglobin at baseline, four to eight weeks, then every three months. Check its lipids at four to eight weeks. Baricitinib and upadacitinib lipid reassessment is around week 12. Continue other blood-count, liver and lipid surveillance according to the specific label and clinical risk, rather than applying one class-wide calendar.
Monitor the whole exposure
Review blood counts, liver tests, lipids, infection, vaccination, renal or hepatic function, gastrointestinal symptoms, thrombosis, and drug interactions using the specific product label.
Quick check
Checking for saved practice…
Lesson
Prevent Complications Before Immunosuppression
Screening, vaccination, laboratory monitoring, and rapid infection response should be designed before therapy begins, then updated whenever the mechanism or disease state changes.
- Tuberculosis
- Hepatitis B
- Vaccines
- Laboratory monitoring
- Serious infection
Every result needs an interpretation and action.
Give indicated vaccines and coordinate selected medication timing.
Treat the infection, define recovery, and document restart ownership.
Screen with a purpose
Review infection history, tuberculosis, hepatitis status, blood counts, liver and renal function, pregnancy, malignancy, and product-specific risks. Pending or abnormal results require interpretation before nonurgent initiation.
Prevent hepatitis B reactivation
Before rituximab, assess HBsAg and anti-HBc in every patient. The ACR strongly favors antiviral prophylaxis over monitoring alone when anti-HBc is positive, regardless of HBsAg status. Coordinate the agent, timing, and follow-up with the hepatitis specialist. Other DMARDs and serologic patterns have different recommendations; a negative surface antigen does not eliminate rituximab reactivation risk.
Vaccinate rather than defer everything
Indicated non-live vaccines remain central during rheumatic disease. The ACR recommends pneumococcal and recombinant zoster vaccination for many immunosuppressed patients and influenza vaccination even during active disease or rituximab use.
Time selected medicines
If disease activity allows, the 2022 ACR vaccination guideline conditionally recommends holding methotrexate for two weeks after influenza vaccination. For rituximab, give influenza vaccine on schedule; other indicated non-live vaccines are generally timed when the next rituximab dose is due, then rituximab is delayed at least two weeks if disease control permits. Do not miss an influenza vaccination opportunity while waiting for a medication-hold discussion.
Respond to serious infection
A serious infection generally prompts interruption of biologic or targeted therapy while the infection is treated. Define source control, recovery, and restart criteria with the treating team rather than using a fixed calendar.
Quick check
Checking for saved practice…
Lesson
Relieve Symptoms Without Losing the Disease
Pain control, glucocorticoids, exercise, rehabilitation, reproductive planning, and access support matter, but each must remain connected to disease modification and long-term safety.
- NSAIDs
- Glucocorticoids
- Exercise
- Pain mechanisms
- Pregnancy planning
NSAIDs and glucocorticoids do not replace a DMARD.
Preserve strength, range, function, participation, and confidence.
Do not escalate immune therapy for clearly noninflammatory pain.
Separate bridge from destination
NSAIDs relieve symptoms without preventing structural progression. Glucocorticoids also suppress inflammation and can slow joint damage, but cumulative toxicity limits their role. They do not replace an effective DMARD strategy. When a glucocorticoid bridge is used, define the lowest effective exposure and a taper plan; distinguish this from indefinite maintenance.
Recognize guideline differences on steroid bridging
EULAR 2025 supports considering short glucocorticoid bridging when starting or changing conventional DMARDs, with prompt withdrawal. ACR 2021 conditionally prefers starting a conventional DMARD without routine short-term steroids and strongly discourages long-term use. Explain the source and patient context; neither endorses indefinite prednisone as a convenient substitute for effective DMARD control.
Explain persistent pain
When objective inflammation is controlled, reassess structural damage, osteoarthritis, tendinopathy, neuropathy, sleep, mood, and central sensitization before escalating immunosuppression.
Prescribe movement and function
Consistent exercise is strongly recommended in the ACR integrative guideline. Tailor mode, intensity, rehabilitation, occupational therapy, joint protection, and assistive devices to current capacity.
Support joints and overall health
Balance activity with short rest periods during flares, use joint-protection or assistive strategies, and support a nutritious diet and healthy weight. Persistent pain or disability from irreversible joint damage may justify orthopedic assessment for repair or replacement. Surgery addresses damaged structures; it does not remove the need to manage systemic disease.
Plan reproduction before exposure
Methotrexate and leflunomide must be replaced before a patient attempts to carry a pregnancy; leflunomide requires documented elimination. Hydroxychloroquine and sulfasalazine are pregnancy-compatible options under specialist care; sulfasalazine needs folic acid supplementation. Control maternal disease while changing treatment. Paternal exposure is a separate question: EULAR 2024 permits methotrexate up to 25 mg weekly and leflunomide in men attempting conception. This differs from U.S. label precautions and requires an explicit specialist discussion, not automatic application of maternal restrictions to fathers.
Distinguish guidance from labeling
The reviewed U.S. methotrexate tablet label calls for contraception during treatment and for six months afterward in females and three months in males; it advises no breastfeeding during treatment and for one week afterward. EULAR's reproductive update uses a shorter preconception interval and permits methotrexate up to 25 mg weekly during lactation only when no compatible alternative can be used. These are differing recommendations, not interchangeable instructions. Document the chosen specialist plan, exact product, exposure role, and alternatives.
Quick check
Checking for saved practice…
Lesson
Reduce Therapy Only After Sustained Remission
Remission changes the treatment question from escalation to preservation. EULAR 2025 favors continuing DMARDs after glucocorticoids are discontinued and remission is sustained; dose reduction may still be considered through shared decisions. Complete withdrawal risks flare.
- Sustained remission
- Shared decision
- Gradual reduction
- Flare monitoring
- Rescue plan
Use repeated objective assessment, not one quiet visit.
Consider gradual reduction only through shared decisions.
Keep monitoring, a rescue plan, and disease-modifying coverage visible.
Confirm that remission is real
Use repeated disease-activity assessment, joint examination, function, symptoms, and relevant markers. A single quiet visit or a suppressed CRP during IL-6 blockade is not enough.
Name the reason to taper
Balance infection, adverse effects, treatment burden, pregnancy plans, cost, and patient preference against the risk of flare and structural progression.
Change one variable
Discuss continuation first. If a reduction is agreed after sustained remission and glucocorticoid discontinuation, reduce a dose or extend an interval gradually with close monitoring. Avoid abrupt complete withdrawal.
Prepare for recurrence
Define early flare features, follow-up timing, laboratory or examination reassessment, and the therapy to restore. A taper is incomplete without a rescue plan.
Quick check
Checking for saved practice…
Lesson
Make the Treatment Timeline Authoritative
Long-term care requires a visible record of disease activity, current and prior mechanisms, response, toxicity, screening, vaccines, and the next decision. A medication list alone cannot provide that continuity.
- Disease activity
- Adherence
- Monitoring
- Remission taper
- Handoff
Record response, toxicity, access, and the reason for every transition.
Capture weekly day, route, last biologic dose, holds, vaccines, and monitoring.
State the target, next review, taper or restart criteria, and responsible clinician.
Measure response consistently
Record a baseline and interpretable follow-up measure. Joint examination remains essential because inflammatory markers can be normal or directly altered by therapies such as IL-6 inhibitors.
Audit adherence and access
Ask whether the patient obtained, administered, stored, and tolerated therapy as intended. Device difficulty, cost, monitoring burden, and health literacy can mimic pharmacologic failure.
Taper only after sustained remission
Continuation is preferred in the EULAR 2025 update after sustained remission and glucocorticoid discontinuation. Individualized reduction remains an option, with objective monitoring and a rescue plan.
Build the handoff
Document weekly methotrexate day, last biologic dose, reason for every prior change, active holds, screening, vaccines, laboratory schedule, pregnancy plan, infection instructions, and who decides when treatment restarts.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 109 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Janssen. Simponi Device Instructions for Use.
- DailyMed. Modified Cyclosporine: RA Indication and Methotrexate Interaction.
- DailyMed. Tacrolimus Ointment: Immune Status and Interaction Precautions.
- DailyMed. Furosemide: Renal Secretion Interactions.
- British Society for Rheumatology. 2025 Conventional DMARD Prescribing and Monitoring Guideline.
- Medexus. Rasuvo Injection Instructions.
- EULAR. Antirheumatic Drugs in Reproduction, Pregnancy, and Lactation: 2024 Update.
- DailyMed. Otrexup Device and Prescribing Information.
- DailyMed. Rasuvo Device and Prescribing Information.
- DailyMed. Remicade Prescribing Information.
- DailyMed. Cimzia Prescribing Information.
- DailyMed. Simponi Prescribing Information.
- DailyMed. Simponi Aria Prescribing Information.
- DailyMed. Kevzara Prescribing Information.
- DailyMed. Azulfidine EN-tabs: Adult RA Dosing and Monitoring.
- DailyMed. Xeljanz and Xeljanz XR: Current Dosing and Safety.
- DailyMed. Olumiant: Indication-Specific Dosing.
- AAO. Hydroxychloroquine Retinopathy Screening: 2025 Revision.
- DailyMed. Enbrel Etanercept: Dosing and Presentation-Specific Storage.
- DailyMed. Kineret Anakinra Prescribing Information.
- DailyMed. Leflunomide Dosing, Monitoring, and Elimination.
- NIAMS. Rheumatoid Arthritis Diagnosis and Treatment.
- American College of Rheumatology. 2021 Guideline for the Treatment of Rheumatoid Arthritis.
- EULAR. 2025 Rheumatoid Arthritis Management Recommendations (published 2026).
- American College of Rheumatology. 2022 Integrative Rheumatoid Arthritis Treatment Guideline.
- Bass AR, et al. 2022 ACR Guideline for Vaccinations in Rheumatic and Musculoskeletal Diseases.
- FDA. Updated Warnings for JAK Inhibitors Used in Chronic Inflammatory Conditions.
- DailyMed. Methotrexate Tablets Prescribing Information.
- DailyMed. Hydroxychloroquine Sulfate Tablets Prescribing Information.
- DailyMed. Orencia Abatacept Prescribing Information.
- DailyMed. Humira Adalimumab Prescribing Information.
- DailyMed. Rituxan Rituximab Prescribing Information.
- DailyMed. Actemra Tocilizumab Prescribing Information.
- DailyMed. Rinvoq Upadacitinib Prescribing Information.